Renzenbrink & Partner advises funds advised by IK Investment Partners (IK VIII Funds) on the acquisition of KLINGEL group

30 May 2018

IK Investment Partners (VIII Funds) has entered into an agreement with Halder regarding the acquisition of KLINGEL group (KLINGEL Beteiligungs GmbH, KLINGEL medical metal GmbH and Josef Ganter GmbH), a leading manufacturer of high-precision, complex metal components for medical technology. The transaction is still subject to clearance by the German federal cartel office.

Founded in 1986, KLINGEL is a leading independent specialist in the manufacturing of high-precision titanium and high-grade stainless steel components. It has an outstanding reputation for quality and its products are used for numerous orthopedic, cardiovascular and dental implants, as well as in endoscopy, dialysis and robotic surgery instruments. KLINGEL supports its customers at every stage of the development process, from conception and prototyping to production, packaging and logistics. Based in Pforzheim, Germany, KLINGEL operates two manufacturing sites and has over 300 employees.

IK and the company’s management team will continue to build on the company’s strong market position, technical know-how and broad customer service offering in order to ultimately add value to the end consumers. In particular, IK will use its considerable expertise in the Contract Manufacturing Organizations (CMO) market to help the company pursue an international growth strategy for its premium quality products.

Renzenbrink & Partner advised IK on all legal and tax aspects of the transaction. The Renzenbrink & Partner team consisted of Dr Ulf Renzenbrink (Private Equity/M&A), Marc H. Kotyrba (Tax), Dr Andreas Stoll (Private Equity/M&A), Dr Gunnar L. Schmüser (Finance), Florian Seitz (Tax), Dr Alexander Haunschild and Martin Degenhard (both Private Equity/M&A).